Diamyd Medical
15.96
SEK
+0.25 %
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
+0.25%
+29.34%
+10.22%
+15.65%
+142.92%
+138.57%
+12.12%
+3.99%
+429.06%
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Read moreMarket cap
1.66B SEK
Turnover
3M SEK
Revenue
130K
EBIT %
-112,746.15 %
P/E
-
Dividend yield-%
-
Financial calendar
29/1
2025
Interim report Q1'25
9/4
2025
Interim report Q2'25
25/6
2025
Interim report Q3'25
ShowingAll content types
Diamyd Medical AB: Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process
Bulletin from Annual General Meeting of Diamyd Medical AB
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
